<DOC>
	<DOCNO>NCT01343277</DOCNO>
	<brief_summary>The purpose study evaluate whether overall survival trabectedin group superior dacarbazine group patient advance L-sarcoma ( liposarcoma leiomyosarcoma ) .</brief_summary>
	<brief_title>A Study Trabectedin Dacarbazine Treatment Patients With Advanced Liposarcoma Leiomyosarcoma</brief_title>
	<detailed_description>This randomize study ( study drug assign chance ) use 2:1 randomization . It open-label ( people know study drug ) , active-controlled ( compare different drug use condition ) , parallel-group ( different treatment group continue separate treatment throughout study ) , multicenter study . This study divide 3 phase , screen , treatment , follow-up optional extension phase ( OEP ) . During screening , potential participant assess study eligibility provide sign informed consent . Approximately 570 patient satisfy inclusion exclusion criterion randomly assign 2:1 ratio either trabectedin ( n=380 ) dacarbazine ( n=190 ) treatment group . During treatment phase , patient receive study drug every 3 week , disease progression ( define Response Evaluation Criteria Solid Tumors [ RECIST ] Version 1.1 criterion ) sign toxicity . Assessments perform evaluate effectiveness drug , patient safety monitor . During follow-up phase , last dose study drug , clinical outcome patient evaluate . Trabectedin administer dose 1.5 milligram per square meter ( mg/m^2 ) catheter large vein 24-hour intravenous ( IV ) infusion , every 3 week , disease progression sign toxicity . Dacarbazine administer dose 1.0 g/m^2 20-120 minute infusion , every 3 week , disease progression sign toxicity . In OEP , participants previously randomize dacarbazine group option receive trabectedin discretion investigator .</detailed_description>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Histologically proven , unresectable , locally advanced metastatic liposarcoma ( dedifferentiate , myxoid round cell , pleomorphic ) leiomyosarcoma . Participants must pathology report indicate diagnosis liposarcoma leiomyosarcoma review sponsor randomization may occur Treated order least : anthracycline ifosfamide contain regimen , anthracycline contain regimen 1 additional cytotoxic chemotherapy regimen Measurable disease baseline accordance RECIST Version 1.1 Pathology specimen ( example [ e.g . ] , tumor block unstained slide ) potential centralized pathology review biomarker study ECOG Performance Status score 0 1 Adequate recovery prior therapy , side effect ( except alopecia ) resolve Grade 1 less accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) Version 4.0 Adequate organ function evidence follow peripheral blood count serum chemistry value : hemoglobin 9 gram per deciliter ( g/dL ) , absolute neutrophil count ( ANC ) 1,500/L , platelet count 100,000/L , serum creatinine 1.5*the upper limit normal ( ULN ) , creatine phosphokinase ( CPK ) 2.5 Upper Limit Normal [ ULN ] Adequate hepatic function evidence follow serum chemistry value : total bilirubin , ULN . If total bilirubin great ( &gt; ) ULN , measure indirect bilirubin evaluate Gilbert 's syndrome ( direct bilirubin within normal range , participant may eligible ) ALP 2.5 x ULN ; Trabectedin : ALP &gt; 2.5 x ULN , ALP liver fraction 5nucleotidase must obtain ULN , AST ALT 2.5 ULN Negative pregnancy test ( urinary serum betaHCG ) screening ( applicable woman child bear potential sexually active ) Female participant must postmenopausal ( spontaneous menses least 2 year ) , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation , otherwise incapable pregnancy ) , abstinent ( discretion investigator ) , sexually active , practice effective method birth control . Male participant must agree use adequate contraception method deem appropriate investigator ( e.g. , vasectomy , doublebarrier , partner use effective contraception ) donate sperm minimum 5 month treatment discontinuation Optional Extension Phase ( OEP ) Phase : Documentation inclusion criterion histologically proven , unresectable , locally advanced metastatic liposarcoma ( dedifferentiate , myxoid round cell , pleomorphic ) leiomyosarcoma . Participants must pathology report indicate diagnosis liposarcoma leiomyosarcoma review sponsor randomization may occur treated order least : anthracycline ifosfamide contain regimen , anthracycline contain regimen 1 additional cytotoxic chemotherapy regimen need review Sponsor Collection specimen : Pathology specimen ( example ( e.g . ) , tumor block unstained slide ) potential centralized pathology review biomarker study applicable Documentation inclusion criterion adequate organ function evidence follow peripheral blood count serum chemistry value : hemoglobin 9 gram per deciliter ( g/dL ) , absolute neutrophil count ( ANC ) 1,500/L , platelet count 100,000/L , serum creatinine 1.5*the upper limit normal ( ULN ) , creatine phosphokinase ( CPK ) 2.5*ULN adequate hepatic function evidence follow serum chemistry value : total bilirubin , ULN . If total bilirubin great ( &gt; ) ULN , measure indirect bilirubin evaluate Gilbert 's syndrome ( direct bilirubin within normal range , participant may eligible ) ALP &lt; = 2.5*ULN ; Trabectedin : ALP &gt; 2.5*ULN , ALP liver fraction 5nucleotidase must obtain ULN , AST ALT 2.5 ULN review Sponsor enrollment OEP may occur Potential participant meet follow criterion exclude participate study : Prior exposure trabectedin dacarabazine , less 3 week last dose systemic cytotoxic therapy , radiation therapy , therapy investigational agent , malignancy within past 3 year . Exceptions : basal nonmetastatic squamous cell carcinoma skin , cervical carcinoma situ , Federation Internationale de Gynecologie et d'Obstetrique ( FIGO ) Stage 1 carcinoma cervix Known central nervous system metastasis Known significant chronic liver disease , cirrhosis active hepatitis ( potential participant test positive hepatitis B surface antigen hepatitis C antibodies allow provide active disease require antiviral therapy ) Myocardial infarct within 6 month enrollment , New York Heart Association Class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemic active conduction system abnormality Uncontrolled intercurrent illness include , limited , poorly control hypertension diabetes , ongoing active infection , psychiatric illness/social situation may potentially impair participant 's compliance study procedure Unwilling unable central venous catheter Known allergy , hypersensitivity , intolerance trabectedin , dacarbazine , dexamethasone , excipients Pregnant breastfeed Any condition , opinion investigator , would compromise wellbeing participant study prevent participant meeting perform study requirement OEP phase : Potential participant meet follow criterion exclude Participating study : Prior exposure trabectedin , less 3 week last dose systemic cytotoxic therapy , radiation therapy , therapy investigational agent , malignancy within past 3 year . Exceptions : basal nonmetastatic squamous cell carcinoma skin , cervical carcinoma situ , Federation Internationale de Gynecologie et d'Obstetrique ( FIGO ) Stage 1 carcinoma cervix apply Treated order least : anthracycline ifosfamide contain regimen , anthracycline contain regimen 1 additional cytotoxic chemotherapy regimen less 3 week last dose systemic anticancer therapy , radiation therapy , therapy investigational agent Known allergy , hypersensitivity , intolerance dacarbazine apply</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Liposarcoma Leiomyosarcoma</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>Anthracycline</keyword>
	<keyword>L-sarcoma</keyword>
</DOC>